Pramlintide
FDA-approved amylin analog (Symlin) for diabetes.
What it's for
Pramlintide is a synthetic analog of amylin, co-secreted with insulin by β-cells. Used with mealtime insulin in type 1 or type 2 diabetes to improve postprandial glucose when insulin alone is insufficient.
What it does for the body
Used with mealtime insulin in type 1 or type 2 diabetes to improve postprandial glucose when insulin alone is insufficient. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
Slows how quickly food leaves the stomach, suppresses postprandial glucagon, and promotes satiety via amylin receptors (lock-and-key landing spots on cells). Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Pramlintide has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Hormones research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Pramlintide — FDA.gov search
- ClinicalTrials.gov search: Pramlintide — U.S. clinical trials registry
- Drugs@FDA search: Pramlintide — FDA drug database (if approved)
- PubMed search: Pramlintide — NCBI PubMed
- PubMed Central search: Pramlintide — NCBI PMC